Vor Biopharma (VOR) Net Income towards Common Stockholders (2020 - 2026)
Vor Biopharma (VOR) reported Net Income towards Common Stockholders of -$31.2 million for Q1 2026, up 3.88% year-over-year from -$30.1 million in Q1 2025, and up 5.85% quarter-over-quarter from -$33.2 million in Q4 2025.
Vor Biopharma (VOR) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends
Vor Biopharma (VOR) has 7 years of Net Income towards Common Stockholders data on file, last reported at -$31.2 million in Q1 2026.
- Net Income towards Common Stockholders for Q1 2026 came in at -$31.2 million, up 3.88% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.5 billion (down 1966.46% YoY), and the FY2025 annual result was -$365.8 million, down 212.86% from the prior year.
- Net Income towards Common Stockholders advanced to -$31.2 million in Q1 2026 per VOR's latest filing, from -$33.2 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at -$21.7 million in Q2 2022 and troughed at -$1.6 billion in Q2 2025.
- A 5-year average of -$165.3 million and a median of -$30.0 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2024 and 2025: Net Income towards Common Stockholders increased 16.97% in 2024, then slumped 5552.75% in 2025.
- A 5-year view of Net Income towards Common Stockholders shows it stood at -$23.9 million in 2022, then fell by 9.83% to -$26.3 million in 2023, then decreased by 16.95% to -$30.7 million in 2024, then fell by 7.99% to -$33.2 million in 2025, then advanced by 5.85% to -$31.2 million in 2026.
- Business Quant data shows VOR's Net Income towards Common Stockholders at -$31.2 million in Q1 2026, -$33.2 million in Q4 2025, and -$812.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | -3.63 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -56.48 Mn |
| 10 | Vor Biopharma | 621.09 Mn | 621.09 Mn | - | -31.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -31.23 Mn |
| Dec 31, 2025 | -33.17 Mn |
| Sep 30, 2025 | -812.68 Mn |
| Jun 30, 2025 | -1.57 Bn |
| Mar 31, 2025 | -32.49 Mn |
| Dec 31, 2024 | -30.71 Mn |
| Sep 30, 2024 | -27.56 Mn |
| Jun 30, 2024 | -27.84 Mn |
| Mar 31, 2024 | -30.80 Mn |
| Dec 31, 2023 | -26.26 Mn |
| Sep 30, 2023 | -33.19 Mn |
| Jun 30, 2023 | -29.98 Mn |
| Mar 31, 2023 | -28.43 Mn |
| Dec 31, 2022 | -23.91 Mn |
| Sep 30, 2022 | -23.79 Mn |
| Jun 30, 2022 | -21.66 Mn |
| Mar 31, 2022 | -22.74 Mn |
| Dec 31, 2021 | -18.25 Mn |
| Sep 30, 2021 | -18.55 Mn |
| Jun 30, 2021 | -18.37 Mn |